PL406631A1 - Antygen, szczepionka przeciwko grypie, układ do wytwarzania szczepionki, sposób wytwarzania antygenu oraz zastosowanie antygenu określonego powyżej do wytwarzania szczepionki przeciwko grypie - Google Patents

Antygen, szczepionka przeciwko grypie, układ do wytwarzania szczepionki, sposób wytwarzania antygenu oraz zastosowanie antygenu określonego powyżej do wytwarzania szczepionki przeciwko grypie

Info

Publication number
PL406631A1
PL406631A1 PL406631A PL40663113A PL406631A1 PL 406631 A1 PL406631 A1 PL 406631A1 PL 406631 A PL406631 A PL 406631A PL 40663113 A PL40663113 A PL 40663113A PL 406631 A1 PL406631 A1 PL 406631A1
Authority
PL
Poland
Prior art keywords
antigen
vaccine
influenza vaccine
producing
production
Prior art date
Application number
PL406631A
Other languages
English (en)
Other versions
PL238555B1 (pl
Inventor
Edyta Kopera
Krystyna Maria Grzelak
Włodzimierz Wiktor Zagórski-Ostoja
Bogusław Szewczyk
Violetta Sączyńska
Katarzyna Florys
Violetta Cecuda-Adamczewska
Original Assignee
Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Instytut Biotechnologii i Antybiotyków
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biochemii I Biofizyki Polskiej Akademii Nauk, Instytut Biotechnologii i Antybiotyków filed Critical Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Priority to PL406631A priority Critical patent/PL238555B1/pl
Priority to EP14830896.8A priority patent/EP3083660B1/en
Priority to PCT/PL2014/000148 priority patent/WO2015093996A1/en
Publication of PL406631A1 publication Critical patent/PL406631A1/pl
Publication of PL238555B1 publication Critical patent/PL238555B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material

Abstract

Ujawniono antygen, szczepionkę przeciwko grypie, układ do wytwarzania szczepionki, sposób wytwarzania antygenu oraz zastosowanie antygenu do wytwarzania szczepionki przeciwko grypie. Wynalazek dotyczy nowego sposobu wytwarzania antygenu szczepionkowego oraz nowego antygenu. Proponowane rozwiązanie prowadzi do uzyskania wysoko immunogennego antygenu co nie wymaga kontaktu z wirusem, a jedynie z genem hemaglutyniny. Szczepionka przeciw grypie nie zawiera wirusa ani jego fragmentów, nie zawiera komórek innych organizmów ani ich fragmentów, a jedynie oczyszczony antygen.
PL406631A 2013-12-20 2013-12-20 Sposób wytwarzania hydrofilowej domeny hemaglutyniny wirusa H5 PL238555B1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL406631A PL238555B1 (pl) 2013-12-20 2013-12-20 Sposób wytwarzania hydrofilowej domeny hemaglutyniny wirusa H5
EP14830896.8A EP3083660B1 (en) 2013-12-20 2014-12-19 Method of influenza antigen production
PCT/PL2014/000148 WO2015093996A1 (en) 2013-12-20 2014-12-19 Antigen, influenza vaccine, system for vaccine manufacturing, method of antigen production, and use of antigen to produce an influenza vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL406631A PL238555B1 (pl) 2013-12-20 2013-12-20 Sposób wytwarzania hydrofilowej domeny hemaglutyniny wirusa H5

Publications (2)

Publication Number Publication Date
PL406631A1 true PL406631A1 (pl) 2015-06-22
PL238555B1 PL238555B1 (pl) 2021-09-06

Family

ID=52424083

Family Applications (1)

Application Number Title Priority Date Filing Date
PL406631A PL238555B1 (pl) 2013-12-20 2013-12-20 Sposób wytwarzania hydrofilowej domeny hemaglutyniny wirusa H5

Country Status (3)

Country Link
EP (1) EP3083660B1 (pl)
PL (1) PL238555B1 (pl)
WO (1) WO2015093996A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL235555B1 (pl) * 2014-06-24 2020-09-07 Inst Biotechnologii I Antybiotykow Wyizolowany i oczyszczony polipeptyd hemaglutyniny (HA ) wirusa grypy H5N1, kompozycja zawierająca polipeptyd i jej zastosowanie, przeciwciało wiążące się specyficznie z polipeptydem oraz sposób otrzymywania tego polipeptydu
PL422982A1 (pl) * 2017-09-26 2019-04-08 Instytut Biochemii I Biofizyki Polskiej Akademii Nauk Antygen uniwersalny, uniwersalna szczepionka przeciwko grypie, układ do wytwarzania szczepionki, sposób wytwarzania antygenu i zastosowanie antygenu do wytwarzania szczepionki uniwersalnej przeciwko grypie

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1945250A4 (en) * 2005-08-16 2010-05-19 Hawaii Biotech Inc RECOMBINANT SUBUNIT VACCINE FOR INFLUENZA VIRUS
US20070286873A1 (en) * 2006-05-23 2007-12-13 Williams John V Recombinant Influenza H5 Hemagluttinin Protein And Nucleic Acid Coding Therefor
WO2012011868A1 (en) * 2010-07-23 2012-01-26 Osterhaus A D M E Influenza vaccine
PL220281B1 (pl) * 2011-09-23 2015-09-30 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciała specyficznie rozpoznające białko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA

Also Published As

Publication number Publication date
EP3083660B1 (en) 2020-02-12
WO2015093996A1 (en) 2015-06-25
EP3083660A1 (en) 2016-10-26
PL238555B1 (pl) 2021-09-06

Similar Documents

Publication Publication Date Title
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
MX2022006603A (es) Vacuna contra el virus de la influenza de amplio espectro.
CY1120319T1 (el) Πρωτεϊνες συντηξης και εμβολια συνδυασμου που περιλαμβανουν haemophilus influenzae πρωτεϊνη ε και πιλινη α
NI201800052A (es) Anticuerpos que neutraliza el virus respiratorio sincitial humano
BR112018008102A2 (pt) vacina de vírus sincicial respiratório
EA202092987A3 (ru) Липид, содержащий докозапентаеновую кислоту
BR112017006736A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes, e métodos de utilização
EA201790630A1 (ru) Способы получения рибозидов
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
MX2015016755A (es) Reagrupamiento del virus de influenza.
MY181068A (en) Recombinant microorganism for improved production of fine chemicals
PH12016501094A1 (en) Recombinant microorganism for improved production of fine chemicals
MX349119B (es) Vacuna de virus de dengue inactivado.
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
MX2018010483A (es) Inmunogenos para vacunacion contra vih.
MX2017016896A (es) Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos.
MA37749B1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
BR112016019390A2 (pt) proteínas de fusão uti
EA201590860A1 (ru) Варианты гемагглютинина и нейраминидазы вируса свиного гриппа
MX2019007924A (es) Vacunas contra la influenza.
MX2015009330A (es) Reordenamiento del virus de influenza.
CL2013001219A1 (es) Metodo para producir virus monoglucosilado de influenza; virus monoglucosilado del antígeno de influenza ha (virus completo o recombinante); uso del virus para preparar vacuna.
PL406631A1 (pl) Antygen, szczepionka przeciwko grypie, układ do wytwarzania szczepionki, sposób wytwarzania antygenu oraz zastosowanie antygenu określonego powyżej do wytwarzania szczepionki przeciwko grypie